思路迪

“成为肿瘤精准医疗领域的创新型领导者”

制药/生物工程 / 500-1000人 / 南宁、昆明、济南等地

新药研发

成员介绍

  • David Liu/CMO

    Engaged in research and development of oncology drugs for nearly 20 years with extensive training in both basic science and clinical medicine; Experienced in global clinical development of biologic and small molecules in both solid and blood malignancies. Former Executive Medical Director at Celgene USA; Former Group Medical Director at BMS

  • Jeffery Lin/Director,Preclinical Drug R&D

    Leads 3DMed bio-marker discovery Former Senior scientist of GSK, responsible for drug screening assay, with rich research experience in epigenetics and leukemia Ph.D in Biochemistry and Molecular Bioloy from Chinese Academy of Sciences, Post-Doc from the Chinese Academy of Science Institute of Health

  • Haolan Lu/Executive Director,Biometrics

    Over 14 years of oncology drug development experience with a proven track of success in immuno-oncology pioneering drugs: Opdivo and Yervoy. Former non-small cell lung cancer indication statistical lead of Bristol-Myers Squibb Company, led registration global approvals for Opdivo in the second and third line treatment of NSCLC PH.D. in Biostatistics from University of Minnesota.

  • Richard Xue/Executive Director,Clinical Operation

    More than 17 years industry experience in drug development including work with hospital, clinical research organisations and biopharmaceutical companies. Previous position span a range of functions, including clinical monitoring,BD,Chang Mangament,training and project management, most recently as global trial lead at Celgene oversaw a successful pivotal trail resulting in globals NDA submissions.

我们的团队

全球首个抗PD-L1单域抗体新药KN035连续推进在中、美、日三地的药物临床试验

新药研发团队在招职位

思路迪的其他团队